NCT04018248 - BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2020

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions

Diffuse Large B Cell LymphomaFollicular LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LeukemiaB Cell LymphomaMarginal Zone LymphomaWaldenstrom MacroglobulinemiaPeripheral T Cell Lymphoma

Interventions

DRUG

BR101801 (Phase Ia)

Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.

DRUG

BR101801 (Phase Ib)

Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.

Trial Locations (9)

48202

Henry Ford Hospital, Detroit

Unknown

National Cancer Center, Goyang-si

Seoul National University Bundang Hospital, Seongnam-si

Chonnam National University Hwasun Hospital, Hwasun

Inje University Busan Paik Hospital, Busan

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul national university hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul